Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2-restricted cytotoxic T-cell responses (Q80445239)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308364%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

title

Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2-restricted cytotoxic T-cell responses (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308364%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308364%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

7

Giuseppe Pantaleo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308364%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1

Arnaud Didierlaurent

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308364%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

9

Mariano Esteban

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308364%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

8

Ralf Wagner

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308364%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Jean-Pierre Kraehenbuhl

10

object named as

Jean-Pierre Kraehenbuhl

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308364%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

author name string

Juan-Carlos Ramirez

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308364%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Magdalena Gherardi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308364%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Simone C Zimmerli

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308364%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Marcus Graf

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308364%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Hans-Acha Orbea

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308364%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

publication date

1 September 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308364%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308364%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308364%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

issue

25-26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308364%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

page(s)

3395-3403

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308364%20AND%20SRC:MED&resulttype=core&format=json

Challenges and opportunities for development of an AIDS vaccine

31 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.025

Prospects for vaccine protection against HIV-1 infection and AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.025

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.025

Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.025

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.025

Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.025

The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.025

Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.025

Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.025

Nonreplicating vaccinia vector efficiently expresses recombinant genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.025

Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.025

MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.025

Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.025

New hope for an AIDS vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.025

Viremia control following antiretroviral treatment and therapeutic immunizationduring primary SIV251 infection of macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.025

Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.025

NYVAC: a highly attenuated strain of vaccinia virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.025

Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.025

Differences in virus-induced cell morphology and in virus maturation between MVA and other strains (WR, Ankara, and NYCBH) of vaccinia virus in infected human cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.025

The use of human leucocyte antigen class I transgenic mice to investigate human immune function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.025

H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.025

Tissue distribution of the Ankara strain of vaccinia virus (MVA) after mucosal or systemic administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.025

Compact, synthetic, vaccinia virus early/late promoter for protein expression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.025

HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.025

Quantification of antigen specific CD8+ T cells using an ELISPOT assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.025

Comparison of cytotoxic T lymphocyte responses induced by peptide or DNA immunization: implications on immunogenicity and immunodominance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.025

Recombinant modified vaccinia virus Ankara efficiently restimulates human cytotoxic T lymphocytes in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.025

Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.025

Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.025

Skewed maturation of memory HIV-specific CD8 T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.025

Complete nucleotide sequence of the AIDS virus, HTLV-III

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.025

Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.025

Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.025

Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.025

Impact of codon usage modification on T cell immunogenicity and longevity of HIV-1 gag-specific DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.025

Codon modified human papillomavirus type 16 E7 DNA vaccine enhances cytotoxic T-lymphocyte induction and anti-tumour activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.025

Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.025

Design of a polyepitope construct for the induction of HLA-A0201-restricted HIV 1-specific CTL responses using HLA-A*0201 transgenic, H-2 class I KO mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.025

Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.025

Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.025

Multiepitopic HLA-A*0201-restricted immune response against hepatitis B surface antigen after DNA-based immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.025

10.1016/J.VACCINE.2004.02.025

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308364%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference